Biopharma Should Copy Our Gilead Deal, Says Rising Star Galapagos
‘Standstill’ Guarantees Biotech’s Independence
$5.1bn alliance is most eyecatching deal of the year – but is only a start for Gilead's rebuilding program.
You may also be interested in...
Scipher Hopes IBD Alliance With Galapagos Is The First Of Many
Focused primarily on developing diagnostic tests to determine whether patients will respond to a drug, Scipher is also using the data from its artificial intelligence process to drive R&D partnerships with drug developers.
Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
European Biotechs Enter the IPO Big League
2019 has seen European biotech companies making waves in the US IPO space. Genmab’s listing was a blockbuster, but many more companies have proven their ability to go public on the NASDAQ.